COVID-19

COVID Recovered Study

Location: Cleveland, OH ; Orlando, FL ; Jackson, TN

Indication: COVID-19

Sponsor: Precision Biospecimen Solutions, Inc.

PI: Hassan Alzoubi, MD ; Christopher Chappel, MD ; Melanie Hoppers, MD

Ages: 18+

Compensation: You may be compensated for your time and participation.

Criteria:

  • Have recovered from a positive COVID-19 case within the past 6 months

About: Clinical Researchers are working to learn more about the effects of COVID-19. A simple sample can help researchers understand more about how our body responds to the virus.

Not Yet COVID Vaccinated Study

Location: Cleveland, OH; Jackson, TN; Orlando, FL

Indication: COVID-19

Sponsor: Precision Biospecimen Solutions, Inc.

PI: Hassan Alzoubi, MD; Melanie Hoppers, MD; Christopher Chappel, MD

Intervention/Treatment: Blood specimen collection

Ages: 18+

Compensation: You may be compensated for your time and participation.

Criteria:

  • Have not received COVID-19 vaccination, but plan to.
  • Have not previously participated in a COVID-19 vaccine study.

About: Researchers are looking for volunteers to donate a sample of their blood prior to receiving the COVID-19 vaccine and after administration of the vaccine.

COVID Treatment Study

Location:  Jackson, TN

Indication:  COVID-19

Sponsor: Revive Therapeutics

PI: Melanie Hoppers, MD

Intervention/Treatment: Bucillamine or placebo

Phase: 3

Ages: 18-80

Compensation: You may be compensated for your time and participation.

Criteria:

  • Male and non-pregnant female patients
  • Must have at least two (2) of the following:
    • Fever, cough, shortness of breath, chest x-ray changes consistent with COVID-19 at time of screening
  • Must have a laboratory-confirmed SARS-CoV-2 infection
  • Must be within 72 hours from receipt of a confirmatory COVID-19 positive test result at time of study
  • Must NOT have a prior history of, or be considered at risk for: agranulocytosis, nephropathy, liver disease or interstitial pneumonia

 

  • There will be 18 total visits. Some will be in person and some will be virtual.

About: Innovative therapies to treat and/or modify the natural course of COVID-19 are urgently needed. Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells. N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase the antioxidant activity of cellular glutathione.

Bucillamine, a cysteine derivative with 2 thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. The drug is non-toxic with high cellular permeability. Extensive experience in Korea with Bucillamine in treating rheumatoid arthritis has established a strong safety record, and there is an open IND to explore its use in treating gout. Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS CoV2 infection in the lungs and attenuate the clinical course of COVID 19.

Antibody Study

Therapeutic Area: Vaccine

Location:  Cleveland, OH; Jackson, TN

Indication:  COVID-19

Sponsor: Adagio

PI: Hassan Alzoubi, MD; Melanie Hoppers, MD, Peter Gardner, MD

Intervention/Treatment: COVID-19 prevention, ADG20 and placebo

Phase: 2/3

Ages: 18+

Criteria:

  • Be at risk of developing COVID-19 (due to your job, housing situation, or lifestyle) OR have recently been exposed to someone who tested positive for COVID-19
  • NOT have had COVID-19 before
  • NOT have received a COVID-19 vaccine

Compensation: You may be compensated for your time and participation.

About: ADG20 is a monoclonal antibody. Antibodies are one of the natural ways the body fights infection. Researchers can also make antibodies (like ADG20) in laboratories and give them to people by injection. ADG20 works by targeting a part of the COVID-19 virus called the “spike protein” which may be able to inactivate the virus.

At Home Study

COVID-19 Home Test

Location: Cleveland

Indication: COVID-19 Home Test

Sponsor: Pure Blue Medical

PI: Lawrence Gervasi, MD

Intervention/Treatment: Test to detect SARS-CoV-2

Ages: 2+

Compensation: You may be compensated for your time and participation.

Criteria:
Experiencing signs and symptoms of COVID-19
Fever
Cough
Shortness of breath
Diarrhea
Difficulty breathing
Muscle pain
Sore throat
Headache
Nausea or vomiting
Chills or shaking with chills
Congestion or runny nose
New loss of taste or smell

 

About: You or your child may qualify for a research study of an investigational test to detect SARS-CoV-2 (COVID-19) infection. If you agree to volunteer, there will be up to three(3) nasal samples collected from your or your child’s nose during today’s office visit.

Antigen Test

Therapeutic Area: Device/COVID-19

Location:  Jackson, TN; Milan, TN

Indication:  COVID-19

Sponsor: Qorvo Biotechnologies

PI: Melanie Hoppers, MD; Peter Gardner, MD

Intervention/Treatment: SARS-CoV-2 Antigen Test

Ages: 2+

Criteria:

  • Symptomatic Subjects
    • 2 COVID-19 signs or symptoms OR
    • Fever of 100.4 +
  • Asymptomatic Subjects
    • Direct contact with a known COVID-19 positive person within 14 days

Compensation: You may be compensated for your time and participation.

About: This is a SARS-CoV-2 Antigen Test to detect whether a subject has Covid-19 using NASAL swabs. This study will collect 4 nasal swabs: 1 to be tested on the study machine at the time of the visit. 1 reference swab is to be sent off the same day as the visit, and the other 2 reference swabs will also be sent off for testing every Monday. We are looking for either symptomatic subjects with at least 2 covid signs and symptoms or a fever of 100.4 or higher. Asymptomatic subjects that have had direct contact with a known positive in the last 14 days.

Start typing and press Enter to search